Bispecific antibody · Immune activation, directed at cadherin-3 (P-cadherin) (CDH3) and mesothelin (MSLN) · developed by AMGEN
AMG 305 is a BiTE bispecific antibody that binds tumor cells co-expressing cadherin-3 (CDH3) and mesothelin (MSLN) and CD3 on cytotoxic T lymphocytes. By cross-linking T cells to these tumor cells, it induces a cytotoxic T-lymphocyte response against them. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid Tumors
Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →